Literature DB >> 28040786

Risk stratification in myelofibrosis: the quest for simplification.

Laura C Michaelis1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28040786      PMCID： PMC5210226          DOI： 10.3324/haematol.2016.158865

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  7 in total

1.  JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.

Authors:  Alessandro M Vannucchi; Lisa Pieri; Paola Guglielmelli
Journal:  Ther Adv Hematol       Date:  2011-02

2.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

4.  JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.

Authors:  G Barosi; C Klersy; L Villani; E Bonetti; P Catarsi; V Poletto; R Campanelli; S Impera; R Latagliata; G Viarengo; A Carolei; M Massa; M Musso; A Crescimanno; R P Gale; V Rosti
Journal:  Leukemia       Date:  2016-02-29       Impact factor: 11.528

5.  Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis.

Authors:  Nicolaus Kröger; Toni Giorgino; Bart L Scott; Markus Ditschkowski; Haefaa Alchalby; Francisco Cervantes; Alessandro Vannucchi; Mario Cazzola; Enrica Morra; Tatjana Zabelina; Margherita Maffioli; Arturo Pereira; Dietrich Beelen; H Joachim Deeg; Francesco Passamonti
Journal:  Blood       Date:  2015-03-17       Impact factor: 22.113

6.  An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.

Authors:  Uri Rozovski; Srdan Verstovsek; Taghi Manshouri; Vilma Dembitz; Ksenija Bozinovic; Kate Newberry; Ying Zhang; Joseph E Bove; Sherry Pierce; Hagop Kantarjian; Zeev Estrov
Journal:  Haematologica       Date:  2016-09-29       Impact factor: 9.941

7.  Effect of mutation order on myeloproliferative neoplasms.

Authors:  Christina A Ortmann; David G Kent; Jyoti Nangalia; Yvonne Silber; David C Wedge; Jacob Grinfeld; E Joanna Baxter; Charles E Massie; Elli Papaemmanuil; Suraj Menon; Anna L Godfrey; Danai Dimitropoulou; Paola Guglielmelli; Beatriz Bellosillo; Carles Besses; Konstanze Döhner; Claire N Harrison; George S Vassiliou; Alessandro Vannucchi; Peter J Campbell; Anthony R Green
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245
  7 in total
  1 in total

1.  Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.

Authors:  Srdan Verstovsek; Shreekant Parasuraman; Jingbo Yu; Anne Shah; Shambhavi Kumar; Ann Xi; Claire Harrison
Journal:  Ann Hematol       Date:  2021-10-09       Impact factor: 3.673
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.